 BOSTON and JERUSALEM, June 28, 2021 GLOBE NEWSWIRE -- Entera Bio Ltd. NASDAQ: ENTX, a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis. EB613 is an oral formulation of human parathyroid hormone 1-34, or PTH, and is positioned to be the first oral bone building anabolic product to treat osteoporosis patients. 